Eisao Innovation and MBC BioLabs Announce 2022 Eisai Golden Ticket Competition to Accelerate Early Drug Discovery and Research Efforts
Eisai Innovation, Inc. (Eisai), and affiliate of Eisai Co., LTD. the fully integrated pharmaceutical company based in Tokyo, Japan, is partnering with MBC BioLabs to award one Golden Ticket to an innovative life science startup.
Eisai is interested in drug discovery platform technologies, novel targets and biology that can be utilized in oncology and neurology.
To apply, submit your non-confidential company presentation using the form below by August 22.
The deck should be a maximum of 10 slides and includes an appendix for any supplemental information.
Please include the following information in your company’s presentation:
- A one-page executive summary of your company
- Your company’s mission
- Key science or technology
- Targeted disease(s), patient populations or issues in healthcare
- Management Team, including advisors
- Non-confidential Intellectual Property or publications that include data supporting your science or technology
- Key milestones, including development and financing
- The competitive landscape
If you have any questions, please email: GoldenTicket@eisaiinnovation.com.
